{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:17:22Z","timestamp":1772641042596,"version":"3.50.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T00:00:00Z","timestamp":1316044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T00:00:00Z","timestamp":1316044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1038\/ijir.2011.45","type":"journal-article","created":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T12:25:32Z","timestamp":1316089532000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Review of non-surgical treatment options for Peyronie's Disease"],"prefix":"10.1038","volume":"24","author":[{"given":"S M","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L A","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,15]]},"reference":[{"key":"BFijir201145_CR1","first-page":"337","volume":"1","author":"F de La Peyronie","year":"1743","unstructured":"de La Peyronie F . Sur quelques obstaclesqui s\u00f3pposent \u00e0 l'\u00e9jaculation nautrelle de la semence. Mem Acad Royale Chir 1743; 1: 337\u2013342.","journal-title":"Mem Acad Royale Chir"},{"key":"BFijir201145_CR2","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0022-5347(01)68236-3","volume":"158","author":"AI El-Sakka","year":"1997","unstructured":"El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF . An animal model of Peyronie's like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997; 158: 2284\u20132290.","journal-title":"J Urol"},{"key":"BFijir201145_CR3","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0022-5347(01)64223-X","volume":"158","author":"AI El-Sakka","year":"1997","unstructured":"El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF . Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 1391\u20131394.","journal-title":"J Urol"},{"key":"BFijir201145_CR4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.ijir.3900874","volume":"14","author":"JP Mulhall","year":"2002","unstructured":"Mulhall JP, Anderson MS, Lubrano T, Shankey TV . Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002; 14: 397\u2013405.","journal-title":"Int J Impot Res"},{"key":"BFijir201145_CR5","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0022-5347(01)65579-4","volume":"156","author":"DA Nachtsheim","year":"1996","unstructured":"Nachtsheim DA, Rearden A . Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J Urol 1996; 156: 1330\u20131334.","journal-title":"J Urol"},{"key":"BFijir201145_CR6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0090-4295(97)00333-6","volume":"50","author":"D Schiavino","year":"1997","unstructured":"Schiavino D, Sasso F, Nucera E, Alcini E, Gulino G, Milani A et al. Immunologic findings in Peyronie's disease: a controlled study. Urology 1997; 50: 764\u2013768.","journal-title":"Urology"},{"key":"BFijir201145_CR7","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1743-6109.2008.00847.x","volume":"5","author":"LP Cantini","year":"2008","unstructured":"Cantini LP, Ferrini MG, Vernet D, Magee TR, Qian A, Gelfand RA et al. Profibrotic role of myostatin in Peyronie's disease. J Sex Med 2008; 5: 1607\u20131622.","journal-title":"J Sex Med"},{"key":"BFijir201145_CR8","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1743-6109.2009.01216.x","volume":"6","author":"JK Ryu","year":"2009","unstructured":"Ryu JK, Piao S, Shin HY, Choi MJ, Zhang LW, Jin HR et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009; 6: 1284\u20131296.","journal-title":"J Sex Med"},{"key":"BFijir201145_CR9","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.juro.2008.01.093","volume":"179","author":"M Del Carlo","year":"2008","unstructured":"Del Carlo M, Cole AA, Levine LA . Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. J Urol 2008; 179: 2447\u20132455.","journal-title":"J Urol"},{"key":"BFijir201145_CR10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1743-6109.2006.00344.x","volume":"4","author":"S Deveci","year":"2007","unstructured":"Deveci S, Hopps CV, O'Brien K, Parker M, Guhring P, Mulhall JP . Defining the clinical characteristics of Peyronie's disease in young men. J Sex Med 2007; 4: 485\u2013490.","journal-title":"J Sex Med"},{"key":"BFijir201145_CR11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-5347(17)66945-3","volume":"114","author":"WL Furlow","year":"1975","unstructured":"Furlow WL, Swenson Jr HE, Lee RE . Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol 1975; 114: 69\u201371.","journal-title":"J Urol"},{"key":"BFijir201145_CR12","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0022-5347(17)39746-X","volume":"144","author":"MK Gelbard","year":"1990","unstructured":"Gelbard MK, Dorey F, James K . The natural history of Peyronie's disease. J Urol 1990; 144: 1376\u20131379.","journal-title":"J Urol"},{"key":"BFijir201145_CR13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","volume":"168","author":"S Deveci","year":"2002","unstructured":"Deveci S, Hopps CV, O'Brien K, Parker M, Guhring P, Mulhall JP . A retrospective review of 307 men with Peyronie's disease. J Urol 2002; 168: 1075\u20131079.","journal-title":"J Urol"},{"key":"BFijir201145_CR14","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","volume":"7","author":"D Ralph","year":"2010","unstructured":"Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M et al. The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med 2010; 7: 2359\u20132374.","journal-title":"J Sex Med"},{"key":"BFijir201145_CR15","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/j.1743-6109.2010.01790.x","volume":"7","author":"AW Shindel","year":"2010","unstructured":"Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G et al. Pentoxifylline attenuates transforming growth factor-\u03b21-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med 2010; 7: 2077\u20132085.","journal-title":"J Sex Med"},{"key":"BFijir201145_CR16","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/j.1743-6109.2010.01749.x","volume":"7","author":"G Lin","year":"2010","unstructured":"Lin G, Shindel AW, Banie L, Ning H, Huang YC, Liu G et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1\/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 2010; 7: 1787\u20131797.","journal-title":"J Sex Med"},{"key":"BFijir201145_CR17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2009.09041.x","volume":"106","author":"MR Safarinejad","year":"2010","unstructured":"Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F . A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int 2010; 106: 240\u2013248.","journal-title":"BJU Int"},{"key":"BFijir201145_CR18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0090-4295(98)00582-2","volume":"53","author":"SE Althof","year":"1999","unstructured":"Althof SE, Corty EW, Levine SB . EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793\u2013799.","journal-title":"Urology"},{"key":"BFijir201145_CR19","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0022-5347(17)66108-1","volume":"81","author":"CJ Zarafonetis","year":"1959","unstructured":"Zarafonetis CJ, Horrax TM . Treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba\u00ae). J Urol 1959; 81: 770\u2013772.","journal-title":"J Urol"},{"key":"BFijir201145_CR20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2340\/00015555721518","volume":"72","author":"MR Griffiths","year":"1992","unstructured":"Griffiths MR, Priestley GC . A comparison of morphoea and lichen sclerosus et atrophicus in vitro: the effects of para-aminobenzoate on skin fibroblasts. Acta Derm Venereol 1992; 72: 15\u201318.","journal-title":"Acta Derm Venereol"},{"key":"BFijir201145_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00005392-199904010-00823","volume":"6","author":"W Weidner","year":"1999","unstructured":"Weidner W, Schroeder-Printzen I, Rudnick J . Randomized prospective placebo controlled therapy of Peyronie's disease (IPP) with Potaba (aminobenzoate potassium). J Urol 1999; 6: 205.","journal-title":"J Urol"},{"key":"BFijir201145_CR22","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","volume":"47","author":"W Weidner","year":"2005","unstructured":"Weidner W, Hauck EW, Schnitker J . Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005; 47: 530\u2013536.","journal-title":"Eur Urol"},{"key":"BFijir201145_CR23","volume-title":"Basic and Clinical Pharmacology","author":"DE Furst","year":"2001","unstructured":"Furst DE, Munster T . Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics & drugs used in gout. In: Bertram G (ed). Basic and Clinical Pharmacology. Katzung Lange: New York, 2001."},{"key":"BFijir201145_CR24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.ijir.3900519","volume":"12","author":"A Kadioglu","year":"2000","unstructured":"Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H . Treatment of Peyronie's disease with oral colchicine: long term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12: 169\u2013175.","journal-title":"Int J Impot Res"},{"key":"BFijir201145_CR25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0090-4295(94)80155-X","volume":"44","author":"E Akkus","year":"1994","unstructured":"Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF . Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994; 44: 291\u2013295.","journal-title":"Urology"},{"key":"BFijir201145_CR26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","volume":"16","author":"MR Safarinejad","year":"2004","unstructured":"Safarinejad MR . Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004; 16: 238\u2013243.","journal-title":"Int J Impot Res"},{"key":"BFijir201145_CR27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","volume":"70","author":"DJ Ralph","year":"1992","unstructured":"Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP . The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992; 70: 648\u2013651.","journal-title":"Br J Urol"},{"key":"BFijir201145_CR28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/bjc.1990.307","volume":"62","author":"AA Colletta","year":"1990","unstructured":"Colletta AA, Wakefield LM, Howell FV, van Roozendaal KE, Danielpour D, Ebbs SR et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62: 405\u2013409.","journal-title":"Br J Cancer"},{"key":"BFijir201145_CR29","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","volume":"162","author":"C Teloken","year":"1999","unstructured":"Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA . Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999; 162: 2003\u20132005.","journal-title":"J Urol"},{"key":"BFijir201145_CR30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","volume":"88","author":"G Biagiotti","year":"2001","unstructured":"Biagiotti G, Cavallini G . Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001; 88: 63\u201367.","journal-title":"BJU Int"},{"issue":"4 Pt 1","key":"BFijir201145_CR31","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","volume":"178","author":"MR Safarinejad","year":"2007","unstructured":"Safarinejad MR, Hosseini SY, Kolahi AA . Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007; 178 (4 Pt 1): 1398\u20131403.","journal-title":"J Urol"},{"key":"BFijir201145_CR32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00007611-194802000-00017","volume":"41","author":"WW Scott","year":"1948","unstructured":"Scott WW, Scardino PL . A new concept in the treatment of Peyronie's disease. South Med J 1948; 41: 173\u2013177.","journal-title":"South Med J"},{"key":"BFijir201145_CR33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.ijir.3900880","volume":"14","author":"SC Sikka","year":"2002","unstructured":"Sikka SC, Hellstrom WJ . Role of oxidative stress and antioxidants in Peyronie's disease. Int J Impot Res 2002; 14: 353\u2013360.","journal-title":"Int J Impot Res"},{"key":"BFijir201145_CR34","first-page":"41","volume":"9","author":"JP Pryor","year":"1983","unstructured":"Pryor JP, Farell CF . Controlled clinical trial of Vitamin E in Peyronie's Disease. Prog Reprod Biol 1983; 9: 41\u201345.","journal-title":"Prog Reprod Biol"},{"issue":"4 Pt 1","key":"BFijir201145_CR35","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","volume":"178","author":"MR Safarinejad","year":"2007","unstructured":"Safarinejad MR, Hosseini SY, Kolahi AA . Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007; 178 (4 Pt 1): 1398\u20131403.","journal-title":"J Urol"},{"key":"BFijir201145_CR36","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","volume":"345","author":"BG Brown","year":"2001","unstructured":"Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583\u20131592.","journal-title":"N Engl J Med"},{"key":"BFijir201145_CR37","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1592\/phco.30.5.540","volume":"30","author":"MJ Fesler","year":"2010","unstructured":"Fesler MJ, Becker-Koepke S, Di Bisceglie AM, Petruska PJ . Procarbazine-induced hepatotoxicity: case report and review of the literature. Pharmacotherapy 2010; 30: 540.","journal-title":"Pharmacotherapy"},{"key":"BFijir201145_CR38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/00365597609179649","volume":"10","author":"J Bystrom","year":"1976","unstructured":"Bystrom J . Induration penis plastica: experience of treatment with procarbazine natulan. Scand J Urol Nephrol 1976; 10: 21\u201325.","journal-title":"Scand J Urol Nephrol"},{"key":"BFijir201145_CR39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1464-410X.1978.tb03038.x","volume":"50","author":"RJ Morgan","year":"1978","unstructured":"Morgan RJ, Pryor JP . Procarbazine (natulan) in the treatment of Peyronie's disease. Br J Urol 1978; 50: 111\u2013113.","journal-title":"Br J Urol"},{"key":"BFijir201145_CR40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/tcrm.2007.3.2.213","volume":"3","author":"JP Armand","year":"2007","unstructured":"Armand JP, Ribrag V, Harroussequ JL, Abrey L . Reappriasal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag 2007; 3: 213\u2013224.","journal-title":"Ther Clin Risk Manag"},{"key":"BFijir201145_CR41","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1073\/pnas.93.11.5478","volume":"93","author":"M Roth","year":"1996","unstructured":"Roth M, Eickelberg O, Kohler E, Erne P, Block LH . Ca2+ channel blockers modulate metabolism of collagens within the extra-cellular matrix. Proc Natl Acad Sci USA 1996; 93: 5478\u20135482.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFijir201145_CR42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.ijir.3900874","volume":"14","author":"JP Mulhall","year":"2002","unstructured":"Mulhall JP, Anderson MS, Lubrano T, Shankey TV . Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002; 14: 397\u2013405.","journal-title":"Int J Impot Res"},{"key":"BFijir201145_CR43","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0022-5347(17)35291-6","volume":"151","author":"LA Levine","year":"1994","unstructured":"Levine LA, Merrick PF, Lee RC . Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994; 151: 1522\u20131524.","journal-title":"J Urol"},{"key":"BFijir201145_CR44","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0022-5347(01)64224-1","volume":"158","author":"LA Levine","year":"1997","unstructured":"Levine LA . Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997; 158: 1395\u20131399.","journal-title":"J Urol"},{"key":"BFijir201145_CR45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","volume":"168","author":"LA Levine","year":"2002","unstructured":"Levine LA, Goldman KE, Greenfield JM . Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002; 168: 621\u2013625.","journal-title":"J Urol"},{"key":"BFijir201145_CR46","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.urology.2007.02.042","volume":"69","author":"NE Bennett","year":"2007","unstructured":"Bennett NE, Guhring P, Mulhall JP . Intralesional verapamil prevents the progression of Peyronie's disease. Urology 2007; 69: 1181\u20131184.","journal-title":"Urology"},{"key":"BFijir201145_CR47","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"JP Mulhall","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P . An analysis of the natural history of Peyronie's disease. J Urol 2006; 175: 2115\u20132118.","journal-title":"J Urol"},{"key":"BFijir201145_CR48","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","volume":"51","author":"J Rehman","year":"1998","unstructured":"Rehman J, Benet A, Melman A . Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998; 51: 620\u2013626. 69: 1181\u20134.","journal-title":"Urology"},{"key":"BFijir201145_CR49","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","volume":"41","author":"M Shirazi","year":"2009","unstructured":"Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S . Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. S Int Urol Nephrol 2009; 41: 467\u2013471.","journal-title":"S Int Urol Nephrol"},{"key":"BFijir201145_CR50","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1111\/j.1743-6109.2010.01924.x","volume":"7","author":"J Soh","year":"2010","unstructured":"Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochiai A, Naitoh Y et al. Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. J Sex Med 2010; 7: 3743\u20133749.","journal-title":"J Sex Med"},{"key":"BFijir201145_CR51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365599109024539","volume":"25","author":"MR Duncan","year":"1991","unstructured":"Duncan MR, Berman B, Nseyo UO . Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25: 89\u201394.","journal-title":"Scand J Urol Nephrol"},{"key":"BFijir201145_CR52","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000475057","volume":"28","author":"HE Wegner","year":"1995","unstructured":"Wegner HE, Andreson R, Knipsel HH, Miller K . Treatment of Peyronie's disease with local interferon-alpha-2b. Eur Urol 1995; 28: 236\u2013240.","journal-title":"Eur Urol"},{"key":"BFijir201145_CR53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000480857","volume":"32","author":"HE Wegner","year":"1997","unstructured":"Wegner HE, Andresen R, Knipsel HH, Miller K . Local inter-feron-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997; 32: 190\u2013193.","journal-title":"Eur Urol"},{"key":"BFijir201145_CR54","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"WJ Hellstrom","year":"2006","unstructured":"Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC et al. Single-blind, multicenter placebo-controlled parallel study to asses the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176: 394\u2013398.","journal-title":"J Urol"},{"key":"BFijir201145_CR55","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","volume":"67","author":"T Inal","year":"2006","unstructured":"Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O . Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology 2006; 67: 1038.","journal-title":"Urology"},{"key":"BFijir201145_CR56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00255956","volume":"10","author":"MK Gelbard","year":"1982","unstructured":"Gelbard MK, Walsh R, Kaufman JJ . Collagenase for Peyronie's disease experimental studies. Urol Res 1982; 10: 135\u2013140.","journal-title":"Urol Res"},{"key":"BFijir201145_CR57","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0022-5347(17)47123-0","volume":"134","author":"MK Gelbard","year":"1985","unstructured":"Gelbard MK, Linkner A, Kaufman JJ . The use of collagenase in the treatment of Peyronie's disease. J Urol 1985; 134: 280\u2013283.","journal-title":"J Urol"},{"key":"BFijir201145_CR58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1743-6109.2007.00651.x","volume":"5","author":"GH Jordan","year":"2008","unstructured":"Jordan GH . The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008; 5: 180\u2013187.","journal-title":"J Sex Med"},{"key":"BFijir201145_CR59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","volume":"149","author":"MK Gelbard","year":"1993","unstructured":"Gelbard MK, James K, Riach P, Dorey F . Collagenase vs. placebo in the treatment of Peyronie's disease: a double blind study. J Urol 1993; 149: 56\u201358.","journal-title":"J Urol"},{"key":"BFijir201145_CR60","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1743-6109.2007.00581.x","volume":"4","author":"S Glina","year":"2007","unstructured":"Glina S, Gelbard MK, Akkus E, Jordan GH, Levine LA . The use of collagenase in the treatment of Peyronie's disease M.K. Gelbard, A. Lindner, and J.J. Kaufman. J Sex Med 2007; 4: 1209\u20131213.","journal-title":"J Sex Med"},{"key":"BFijir201145_CR61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1745-7262.2008.00351.x","volume":"10","author":"FL Taylor","year":"2008","unstructured":"Taylor FL, Levine LA . Nonsurgical therapy of Peyronie's Disease. Asian J Androl 2008; 10: 79\u201387.","journal-title":"Asian J Androl"},{"key":"BFijir201145_CR62","first-page":"32","volume":"20","author":"H Bodner","year":"1953","unstructured":"Bodner H, Howard AH, Kaplan JH . Peyronie's Disease cortisone-hyaluronidase hydrocortisone therapy. Trans West Sect AM Urol Assoc 1953; 20: 32\u201335.","journal-title":"Trans West Sect AM Urol Assoc"},{"key":"BFijir201145_CR63","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0022-5347(17)67169-6","volume":"114","author":"CC Winter","year":"1975","unstructured":"Winter CC, Khanna R . Peyronie's Disease: results with dermojet injection of dexamethasone. J Urol 1975; 114: 898\u2013900.","journal-title":"J Urol"},{"key":"BFijir201145_CR64","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1464-410X.1980.tb03067.x","volume":"52","author":"G Williams","year":"1980","unstructured":"Williams G, Green NA . The nonsurgical treatment of Peyronie's Disease. Br J Urol 1980; 52: 392\u2013395.","journal-title":"Br J Urol"},{"key":"BFijir201145_CR65","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2164\/jandrol.109.008029","volume":"31","author":"R Dickstein","year":"2010","unstructured":"Dickstein R, Uberoi J, Munarriz R . Severe, disabling, and\/or chronic penile pain associated with Peyronie's Disease: management with subcutaneous steroid injection. J Androl 2010; 31: 445\u2013449.","journal-title":"J Androl"},{"key":"BFijir201145_CR66","first-page":"250","volume":"4","author":"G Bartsch","year":"1981","unstructured":"Bartsch G, Menander-Huber KB, Huber W, Marberger H . Orgotein, A new drug for the treatment of Peyronie's Disease. Eur J Rheumatol Inflamm 1981; 4: 250\u2013259.","journal-title":"Eur J Rheumatol Inflamm"},{"key":"BFijir201145_CR67","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000473262","volume":"7","author":"H Gustafson","year":"1981","unstructured":"Gustafson H, Johannsson B, Edsmyr F . Peyronie's Disease: experience of local treatment with orgotein. Eur Urol 1981; 7: 346\u2013348.","journal-title":"Eur Urol"},{"key":"BFijir201145_CR68","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-1-59745-161-1_7","volume-title":"Peyronie's Disease: A Guide to Clinical Management","author":"M Kendirci","year":"2007","unstructured":"Kendirci M, Trost L, Hellstrom WJG . Intralesional treatment of Peyronie's Disease. In: Levine LA (ed). Peyronie's Disease: A Guide to Clinical Management. Humana Pres Inc: Totowa, NJ, 2007, pp 81\u201392."},{"key":"BFijir201145_CR69","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.urology.2009.03.017","volume":"74","author":"I Stancik","year":"2009","unstructured":"Stancik I, Sch\u00e4fer R, Andrukhova O, Oeser R, Plas E, Pfl\u00fcger H . Effect of transdermal electromotive drug therapy on fibrogenic cytokine expression in Peyronie's disease. Urology 2009; 74: 566\u2013570.","journal-title":"Urology"},{"key":"BFijir201145_CR70","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","volume":"177","author":"JM Greenfield","year":"2007","unstructured":"Greenfield JM, Shah SJ, Levine LA . Verapamil versus saline in electromotive drug administration (EDMA) for Peyronie's disease: a double blind, placebo controlled trial. J Urol 2007; 177: 972\u2013975.","journal-title":"J Urol"},{"key":"BFijir201145_CR71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/archderm.1990.01670260092018","volume":"126","author":"DS Weiss","year":"1990","unstructured":"Weiss DS, Kirsner R, Eaglestein WH . Electrical stimulation and wound healing. Arch Dermatol 1990; 126: 222\u2013225.","journal-title":"Arch Dermatol"},{"key":"BFijir201145_CR72","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1464-410X.2003.04242.x","volume":"91","author":"SM Di Stasi","year":"2003","unstructured":"Di Stasi SM, Giannantoni A, Capelli G, Jannini EA, Virgili G, Storti L et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int 2003; 91: 825\u2013829.","journal-title":"BJU Int"},{"key":"BFijir201145_CR73","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1038\/sj.ijir.3901084","volume":"15","author":"LA Levine","year":"2003","unstructured":"Levine LA . Review of current nonsurgical management of Peyronie's disease. Int J Impot Res 2003; 15: S113\u2013S120.","journal-title":"Int J Impot Res"},{"key":"BFijir201145_CR74","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1159\/000020359","volume":"38","author":"EW Hauck","year":"2000","unstructured":"Hauck EW, Altinkilic BM, Ludwig M, Ludecke G, Schroeder-Printzen I, Arens C et al. Extracorporeal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach. Eur Urol 2000; 38: 663\u2013670.","journal-title":"Eur Urol"},{"key":"BFijir201145_CR75","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","volume":"56","author":"A Palmieri","year":"2009","unstructured":"Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009; 56: 363\u2013369.","journal-title":"Eur Urol"},{"key":"BFijir201145_CR76","doi-asserted-by":"crossref","first-page":"PE6","DOI":"10.1126\/stke.2002.119.pe6","volume":"2002","author":"FJ Alenghat","year":"2002","unstructured":"Alenghat FJ, Ingber DE . Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins. Sci STKE 2002; 2002: PE6.","journal-title":"Sci STKE"},{"key":"BFijir201145_CR77","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jor.1100130111","volume":"13","author":"BA Alman","year":"1995","unstructured":"Alman BA, Naber SP, Terek RM, Jiranek WA, Goldberg MJ, Wolfe HJ . Platelet-derived growth factor in fibrous musculoskeletal disorders: a study of pathologic tissue sections and in vitro primary cell cultures. J Orthop Res 1995; 13: 67\u201377.","journal-title":"J Orthop Res"},{"key":"BFijir201145_CR78","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2106\/00004623-199609000-00007","volume":"78","author":"CT Brighton","year":"1996","unstructured":"Brighton CT, Fisher Jr JR, Levine SE, Corsetty JR, Reilly T, Landsman AS et al. The biochemical pathway mediating the proliferative response of bone cells to a mechanical stimulus. J Bone Joint Surg AM 1996; 78: 1337\u20131347.","journal-title":"J Bone Joint Surg AM"},{"key":"BFijir201145_CR79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1054\/bjps.1997.3044","volume":"52","author":"G Molea","year":"1999","unstructured":"Molea G, Schonauer F, Blasi F . Progressive skin extension: clinical and histological evaluation of a modified procedure using Kirschner wires. Br J Plast Surg 1999; 52: 205\u2013208.","journal-title":"Br J Plast Surg"},{"key":"BFijir201145_CR80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.22203\/eCM.v015a05","volume":"15","author":"F Shapiro","year":"2008","unstructured":"Shapiro F . Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater 2008; 15: 53\u201376.","journal-title":"Eur Cell Mater"},{"key":"BFijir201145_CR81","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.prs.0000182345.86453.4f","volume":"116","author":"KD Fong","year":"2005","unstructured":"Fong KD, Trindade MC, Wang Z, Nacamuli RP, Pham H, Fang TD et al. Microarray analysis of mechanical shear effects on flexor tendon cells. Plast Reconstr Surg 2005; 116: 1393\u20131404.","journal-title":"Plast Reconstr Surg"},{"key":"BFijir201145_CR82","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1586\/17434440.5.3.305","volume":"5","author":"LA Levine","year":"2008","unstructured":"Levine LA, Newell MM . FastSize Medical Extender for the treatment of Peyronie's disease. Expert Rev Med Devices 2008; 5: 305\u2013310.","journal-title":"Expert Rev Med Devices"},{"key":"BFijir201145_CR83","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1743-6109.2008.01108.x","volume":"6","author":"P Gontero","year":"2009","unstructured":"Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med 2009; 6: 558\u2013566.","journal-title":"J Sex Med"},{"key":"BFijir201145_CR84","first-page":"37","volume":"1. pii","author":"JM Greenfield","year":"2009","unstructured":"Greenfield JM . Penile traction therapy in Peyronie's disease. F1000 Med Rep 2009; 1. pii: 37.","journal-title":"F1000 Med Rep"},{"issue":"Suppl 4","key":"BFijir201145_CR85","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(08)61194-5","volume":"179","author":"MR Abern","year":"2008","unstructured":"Abern MR, Levine LA . Intralesional verapamil injections with and without penile traction and oral therapies for management of Peyronie's disease. J Urol 2008; 179 (Suppl 4): 408.","journal-title":"J Urol"},{"key":"BFijir201145_CR86","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2165\/00003495-200767040-00004","volume":"67","author":"LW Trost","year":"2007","unstructured":"Trost LW, Gur S, Hellstrom WJ . Pharmacological management of Peyronie's disease. Drugs 2007; 67: 527\u2013545.","journal-title":"Drugs"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ijir201145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijir201145","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijir201145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T16:36:41Z","timestamp":1712853401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijir201145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,15]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["BFijir201145"],"URL":"https:\/\/doi.org\/10.1038\/ijir.2011.45","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,15]]},"assertion":[{"value":"22 February 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Laurence A Levine, Auxilium consultant, investigator, speaker; AMS consultant, speaker; Coloplast consultant, speaker; US Physiomed consultant; Pfizer consultant; Slate pharmaceutical consultant. Stephen M Larsen declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}